Dr. Siegel on the Importance of Investigating Ide-cel in Multiple Myeloma
David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma
David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.
ASH Takeaways and Future Directions for Multiple Myeloma
Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.
Sequencing BCMA-Targeted Agents in RRMM
Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM.
Non-BCMA Specific Targets in RRMM
Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM.
Investigational BCMA Targets in RRMM
Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM.
Targeting BCMA and CAR T Therapy in RRMM
Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM.
Emerging Novel Agents in RRMM
Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM.
Using PI-based Combinations in RRMM
Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.
Role of IMiD-based Strategies for RRMM
Approaching Treatment of RRMM
Future of MRD Assessment in NDMM
ASH Updates on Transplant in NDMM
Individualized Induction Therapy for NDMM
Approaching Early Treatment of High-Risk SMM
Role of Therapeutic Intervention in SMM
Overview of Smoldering Multiple Myeloma
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512